Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 5:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 261 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Respiratory Infections in Children Clear all
Terminated Phase 3 Interventional Results available

A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia

NCT01110421
View directory record Official record
Conditions
Pneumonia, Bacterial, Community-Acquired Infections, Nosocomial Infection, Pneumonia, Ventilator-Associated
Interventions
Cefepime placebo, Cefepime, Doripenem, Doripenem placebo, Amoxicillin/clavulanate potassium
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
3 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 28, 2026, 5:23 AM EDT
Completed No phase listed Observational

Sinusitis in Children and the Nasopharyngeal Microbiome

NCT01492868
View directory record Official record
Conditions
Sinusitis
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
4 Years to 7 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 28, 2026, 5:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pandemic-adapted Caries Care Multicentre Single-group Interventional Study

NCT04666597
View directory record Official record
Conditions
Dental Caries in Children
Interventions
Modified CariesCare International management
Procedure
Lead sponsor
Universidad El Bosque, Bogotá
Other
Eligibility
3 Years to 8 Years
Enrollment
409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2023 · Synced Sep 28, 2026, 5:23 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

NCT04919109
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
CodaVax-RSV, Normal Saline
Biological
Lead sponsor
Codagenix, Inc
Industry
Eligibility
6 Months to 5 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
4
States / cities
Lincoln, Nebraska • Omaha, Nebraska • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 28, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT02601612
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
D46cpΔM2-2 vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 60 Months
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 28, 2026, 5:23 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age

NCT04544267
View directory record Official record
Conditions
Influenza
Interventions
Quadrivalent influenza vaccine, high-dose, Quadrivalent influenza vaccine, standard dose
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 35 Months
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
10
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 28, 2026, 5:23 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

BinaxNOW for Evaluating Children for Infection With SARS-CoV-2 (COVID-19)

NCT05087524
View directory record Official record
Conditions
SARS-CoV2 Infection, COVID-19
Interventions
BinaxNOW Ag Card
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
5 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Sep 28, 2026, 5:23 AM EDT
Withdrawn No phase listed Observational

Clinical Pediatric Pneumonia Score in Critically Ill Children

NCT02139384
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
Not listed
Lead sponsor
Loma Linda University
Other
Eligibility
1 Day to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2017 · Synced Sep 28, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection

NCT01715909
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Up to 12 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Sep 28, 2026, 5:23 AM EDT
Terminated Phase 3 Interventional

TELI TON - Telithromycin in Tonsillitis

NCT00315042
View directory record Official record
Conditions
Tonsillitis, Pharyngitis
Interventions
Telithromycin (HMR3647), Penicillin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Months to 13 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 2, 2009 · Synced Sep 28, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.

NCT01855945
View directory record Official record
Conditions
Prophylaxis of A/H3N2v Influenza
Interventions
Swine Influenza
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
3 Years to 92 Years
Enrollment
627 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
11
States / cities
Redding, California • Sacramento, California • Lenexa, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2016 · Synced Sep 28, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility of Cocooning Immunization Strategy With Influenza Vaccine

NCT00570037
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
544 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Sep 28, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age

NCT03698279
View directory record Official record
Conditions
Influenza
Interventions
High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated), High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated), Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated), FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 17 Years
Enrollment
665 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
13
States / cities
San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 28, 2026, 5:23 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics

NCT00336453
View directory record Official record
Conditions
Influenza
Interventions
Influenza Vaccination
Biological
Lead sponsor
Protein Sciences Corporation
Industry
Eligibility
6 Months to 59 Months
Enrollment
156 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
3
States / cities
Bardstown, Kentucky • St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 16, 2009 · Synced Sep 28, 2026, 5:23 AM EDT
Recruiting Not applicable Interventional

Lateral Pharyngoplasty Outcomes in Children Undergoing Tonsillectomy

NCT05575401
View directory record Official record
Conditions
Sleep-Disordered Breathing, Sleep Apnea Syndromes in Children, Sleep Apnea, Obstructive, Tonsillitis, Tonsillar Hypertrophy, Tonsil Stone, Tonsil Disease
Interventions
Lateral pharyngoplasty, Tonsillectomy
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
3 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Murrieta, California • Riverside, California • San Bernardino, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 28, 2026, 5:23 AM EDT
Completed No phase listed Observational

Vitamin D Levels in Children Undergoing Adenotonsillectomies and Controls

NCT00829972
View directory record Official record
Conditions
Tonsillitis
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
1 Year to 12 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 5, 2023 · Synced Sep 28, 2026, 5:23 AM EDT
Completed Not applicable Interventional Results available

Sinus Balloon Dilation in Pediatric Patients

NCT02278484
View directory record Official record
Conditions
Sinusitis
Interventions
XprESS device and PathAssist confirmation tools
Device
Lead sponsor
Entellus Medical, Inc.
Industry
Eligibility
2 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Phoenix, Arizona • Salem, Oregon • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Sep 28, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children

NCT01459198
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MEDI ΔM2-2 vaccine, Placebo vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 49 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Sep 28, 2026, 5:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Influenza Immunity in Children

NCT02559505
View directory record Official record
Conditions
Influenza
Interventions
Seasonal IIV 0.25 mL dose, Natural influenza infection, Seasonal IIV 0.5 mL dose
Biological · Other
Lead sponsor
University of Rochester
Other
Eligibility
3 Months to 8 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Sep 28, 2026, 5:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age

NCT01974895
View directory record Official record
Conditions
Influenza
Interventions
FluLaval® Quadrivalent, Fluzone®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 35 Months
Enrollment
316 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
12
States / cities
Sacramento, California • West Covina, California • Altamonte Springs, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Sep 28, 2026, 5:23 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months

NCT00996307
View directory record Official record
Conditions
Influenza
Interventions
MF59-eH1N1_f
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
6 Months to 35 Months
Enrollment
654 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
28
States / cities
Bentonville, Arkansas • Fort Smith, Arkansas • Canoga Park, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 28, 2026, 5:23 AM EDT
Completed Phase 1 Interventional

Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

NCT00910351
View directory record Official record
Conditions
Pseudomonas Infection
Interventions
Ciprofloxacin (Cipro, BAYQ3939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Years to 12 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Sep 28, 2026, 5:23 AM EDT
Withdrawn No phase listed Observational

Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children

NCT00645619
View directory record Official record
Conditions
Viral Pneumonia, Bacterial Pneumonia
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 28, 2026, 5:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT02237209
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV LID ΔM2-2 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
7
States / cities
Alhambra, California • La Jolla, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Sep 28, 2026, 5:23 AM EDT